The idea that our immune system can be rewired to fight cancer has resulted in huge expectations and an influx of investments into the immuno-oncology field. Following the market success of immune checkpoint inhibitors, more and more attention is turning to CAR-T cell therapy, with the first CAR-T therapy, Novartis’ Kymriah, approved in 2017.
With five CAR-T therapies on the global market already and over hundreds of clinical trials currently running, the field is now booming. Read on to keep up-to-date with the evolving CAR-T cell therapy market and ongoing research.
A Guide to Current Therapies in Immuno-Oncology
From a rich history to a growing number of therapies, the immuno-oncology landscape has changed rapidly over the last decade. In this report, we look into its past, discuss present therapeutic approaches, and provide an outlook into its future.
Go to ReportA new case of blood cancer gets diagnosed approximately every three minutes in Western countries.…
Legend Biotech Corporation has announced that the U.S. Food and Drug Administration (FDA) has cleared…
SOTIO Biotech has presented preclinical results of its BOXR T cell therapy platform and revealed…
The Peter MacCallum Cancer Centre (Peter Mac) and Cartherics Pty Ltd (Cartherics) have entered into…
Elicera Therapeutics AB has entered a material transfer agreement with the Josep Carreras Leukaemia Research…
The companies Acelyrin, InnovaFeed and Arsenal Biosciences bagged the biggest biotech investments in September 2022,…
Mission Bio has announced the availability of the Tapestri VCN Assay, the first high-throughput commercial…
Positive results from a phase 1 clinical study of RD13-01, an anti-CD7 universal CAR-T therapy…
Kai Pinkernell, chief medical officer at Glycostem, discusses how natural killer (NK) cell therapies could…
Despite its meteoric growth in the last twenty years, cancer immunotherapy research is hamstrung by…
The manufacturing of cell therapies is highly complex, often depending on skilled manual labor. The…
India is brimming with biotech companies and a young and skilled workforce. Here’s a quick…
